JP2015514115A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514115A5 JP2015514115A5 JP2015504730A JP2015504730A JP2015514115A5 JP 2015514115 A5 JP2015514115 A5 JP 2015514115A5 JP 2015504730 A JP2015504730 A JP 2015504730A JP 2015504730 A JP2015504730 A JP 2015504730A JP 2015514115 A5 JP2015514115 A5 JP 2015514115A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- polypeptide
- amino acid
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261621154P | 2012-04-06 | 2012-04-06 | |
| US61/621,154 | 2012-04-06 | ||
| PCT/US2013/035305 WO2013152213A1 (en) | 2012-04-06 | 2013-04-04 | Methods and compositions for increasing red blood cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017144654A Division JP2017190344A (ja) | 2012-04-06 | 2017-07-26 | 赤血球を増加させるための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514115A JP2015514115A (ja) | 2015-05-18 |
| JP2015514115A5 true JP2015514115A5 (https=) | 2016-06-02 |
| JP6234993B2 JP6234993B2 (ja) | 2017-11-22 |
Family
ID=49301055
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015504730A Expired - Fee Related JP6234993B2 (ja) | 2012-04-06 | 2013-04-04 | 赤血球を増加させるための方法および組成物 |
| JP2017144654A Withdrawn JP2017190344A (ja) | 2012-04-06 | 2017-07-26 | 赤血球を増加させるための方法および組成物 |
| JP2019123059A Withdrawn JP2019156858A (ja) | 2012-04-06 | 2019-07-01 | 赤血球を増加させるための方法および組成物 |
| JP2021077695A Pending JP2021107453A (ja) | 2012-04-06 | 2021-04-30 | 赤血球を増加させるための方法および組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017144654A Withdrawn JP2017190344A (ja) | 2012-04-06 | 2017-07-26 | 赤血球を増加させるための方法および組成物 |
| JP2019123059A Withdrawn JP2019156858A (ja) | 2012-04-06 | 2019-07-01 | 赤血球を増加させるための方法および組成物 |
| JP2021077695A Pending JP2021107453A (ja) | 2012-04-06 | 2021-04-30 | 赤血球を増加させるための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US9809636B2 (https=) |
| EP (2) | EP3351260B1 (https=) |
| JP (4) | JP6234993B2 (https=) |
| AU (3) | AU2013243388B2 (https=) |
| CA (1) | CA2869474C (https=) |
| WO (1) | WO2013152213A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9809636B2 (en) * | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| GB201412290D0 (en) * | 2014-07-10 | 2014-08-27 | Cambridge Entpr Ltd | Novel use |
| CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| EP3303387A2 (en) | 2015-06-05 | 2018-04-11 | Novartis AG | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor |
| WO2017079591A2 (en) | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| DK3496739T3 (da) | 2016-07-15 | 2021-05-10 | Acceleron Pharma Inc | Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| KR20220021207A (ko) * | 2020-08-13 | 2022-02-22 | 주식회사 나이벡 | 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| EP0592562B1 (en) | 1991-06-25 | 1999-01-07 | Genetics Institute, Inc. | Bmp-9 compositions |
| JPH08510446A (ja) * | 1993-03-04 | 1996-11-05 | クリエイティブ バイオモレキュルズ，インコーポレイテッド | 組換え骨形成タンパク質を生成するための方法および組成物 |
| JPH09501305A (ja) | 1993-05-12 | 1997-02-10 | ジェネティックス・インスティテュート・インコーポレイテッド | Ｂｍｐ−１０組成物 |
| US5637480A (en) | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
| US6034062A (en) | 1997-03-13 | 2000-03-07 | Genetics Institute, Inc. | Bone morphogenetic protein (BMP)-9 compositions and their uses |
| US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| WO2005113590A2 (en) | 2004-05-12 | 2005-12-01 | Acceleron Pharma Inc. | Bmp10 propeptides and related methods |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| EP1863518A2 (en) * | 2005-03-30 | 2007-12-12 | Wyeth | Methods for stimulating hair growth by administering bmps |
| ES2649983T3 (es) | 2005-11-23 | 2018-01-16 | Acceleron Pharma, Inc. | Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo |
| GB0615129D0 (en) | 2006-07-29 | 2006-09-06 | Univ Cardiff | Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies |
| CN104524548A (zh) | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
| MX2009008222A (es) | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EA018221B1 (ru) | 2007-02-09 | 2013-06-28 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ |
| CN101861161B (zh) | 2007-09-18 | 2017-04-19 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| JP5638961B2 (ja) * | 2008-03-13 | 2014-12-10 | ザ ジェネラル ホスピタル コーポレイション | Ｂｍｐシグナル伝達経路のインヒビター |
| JP5719766B2 (ja) | 2008-05-02 | 2015-05-20 | アクセルロン ファーマ， インコーポレイテッド | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
| CA2724525A1 (en) | 2008-05-15 | 2009-11-19 | Acceleron Pharma, Inc. | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
| DK2318028T3 (da) | 2008-06-26 | 2020-05-04 | Acceleron Pharma Inc | Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer |
| TW201803586A (zh) | 2008-08-14 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| KR20180026795A (ko) | 2009-06-12 | 2018-03-13 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| AU2010282361B2 (en) | 2009-08-13 | 2015-03-19 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
| JP2012238811A (ja) | 2011-05-13 | 2012-12-06 | Toshiba Corp | 半導体不揮発性記憶装置およびその製造方法 |
| US9809636B2 (en) * | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| CN104411720B (zh) * | 2012-07-02 | 2018-05-11 | 协和发酵麒麟株式会社 | 以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂 |
| US20180125928A1 (en) | 2015-05-13 | 2018-05-10 | Celgene Corporation | Treatment of beta-thalassemia using actrii ligand traps |
-
2013
- 2013-03-14 US US13/827,477 patent/US9809636B2/en active Active
- 2013-04-04 CA CA2869474A patent/CA2869474C/en active Active
- 2013-04-04 EP EP17208236.4A patent/EP3351260B1/en active Active
- 2013-04-04 AU AU2013243388A patent/AU2013243388B2/en not_active Ceased
- 2013-04-04 WO PCT/US2013/035305 patent/WO2013152213A1/en not_active Ceased
- 2013-04-04 EP EP13772302.9A patent/EP2844272A4/en not_active Withdrawn
- 2013-04-04 JP JP2015504730A patent/JP6234993B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-26 JP JP2017144654A patent/JP2017190344A/ja not_active Withdrawn
- 2017-10-13 US US15/783,056 patent/US10344066B2/en active Active
-
2018
- 2018-04-03 AU AU2018202326A patent/AU2018202326B2/en not_active Ceased
-
2019
- 2019-05-24 US US16/422,117 patent/US10829534B2/en active Active
- 2019-07-01 JP JP2019123059A patent/JP2019156858A/ja not_active Withdrawn
-
2020
- 2020-10-06 US US17/063,848 patent/US11807673B2/en active Active
-
2021
- 2021-02-24 AU AU2021201196A patent/AU2021201196A1/en not_active Abandoned
- 2021-04-30 JP JP2021077695A patent/JP2021107453A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514115A5 (https=) | ||
| Merten et al. | Viral vectors for gene therapy and gene modification approaches | |
| JP2017533910A5 (https=) | ||
| JP2013501816A5 (https=) | ||
| JP2015518818A5 (https=) | ||
| JP2014512171A5 (https=) | ||
| JP2014513952A5 (https=) | ||
| JP2015517488A5 (https=) | ||
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| FI3310809T3 (fi) | Anti-cgrp-vasta-aineformulaatio | |
| JP2014503206A5 (https=) | ||
| JP2016501528A5 (https=) | ||
| JP2016538885A5 (https=) | ||
| JP2015508771A5 (https=) | ||
| RU2017101705A (ru) | Фармацевтическая композиция, предназначенная для применения для предупреждения и/или лечения заболевания, которое развивается или прогрессирует вследствие снижения или утраты активности фактора свертывания крови viii и/или активированного фактора свертывания крови viii | |
| JP2012529436A5 (https=) | ||
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| RU2015128078A (ru) | Композиции и способы лечения рака мозга | |
| PH12014500865A1 (en) | Compounds and methods for enhancing innate immune responses | |
| JP2017532343A5 (https=) | ||
| EA201400963A1 (ru) | Фармацевтический препарат, содержащий производное дигидрохиназолина с противовирусной активностью | |
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| RU2016108808A (ru) | Терапевтическое применение vegf-c и ccbe1 | |
| JP2018527941A5 (https=) | ||
| JP2016517421A5 (https=) |